Abstract
Background Obesity and hypertension are major public health problems and are associated with adverse health outcomes. To model realistic prevention scenarios and inform policy, it may be helpful to conceptualise early lifecourse domains of risk and incorporate such information when predicting comorbidity outcomes. We identify exposures across five pre-hypothesised childhood domains and explore them as predictors of obesity and hypertension comorbidity in adulthood.
Methods The analytical sample included 7858 participants in the 1970 British Cohort Study. The outcome was obesity (BMI of ≥30) and hypertension (blood pressure>140/90mm Hg or self-reported doctor’s diagnosis) comorbidity at age 46. Early life domains included: ‘prenatal, antenatal, neonatal and birth’, ‘developmental attributes and behaviour’, ‘child education and academic ability’, ‘socioeconomic factors’ and ‘parental and family environment’. We conducted prediction analysis of the outcome in three stages:(1) stepwise backward elimination to select variables for inclusion for each domain (2) calculation of predicted risk scores of obesity-hypertension for each cohort member within each domain (3) multivariable logistic regression analysis including domain-specific risk scores, sex and ethnicity to assess how well the outcome could be predicted. We additionally included potential adult predictors of obesity-hypertension comorbidity as sensitivity analysis.
Results Including all domain-specific risk scores in the same model, all five domains were significant predictors of obesity-hypertension comorbidity. The predictive power of the model, measured by the area under the curve (AUC), was 0.63 (95%CI 0.61-0.65). Including adult predictors increase the AUC to 0.68 (95%CI 0.66-0.70), and three early life domains - the parental and family environment domain (OR 1.11 95%CI 1.05-1.17) the socioeconomic factors domain (OR 1.09 95%CI 1.04-1.16), and the education and academic ability domain (OR 1.07 95%CI 1.02-1.13) remained predictors of obesity-hypertension comorbidity.
Conclusions We found three robust domains for predicting obesity-hypertension comorbidity. Interventions that address these early life factors could reduce the burden of comorbidity.
Competing Interest Statement
R.O. is a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee, member of the NICE Decision Support Unit (DSU), and associate member of the NICE Technical Support Unit (TSU). She has served as a paid consultant to the pharmaceutical industry and international reimbursement agencies, providing unrelated methodological advice. She reports teaching fees from the Association of British Pharmaceutical Industry (ABPI). R.H. is a member of the Scientific Board of the Smith Institute for Industrial Mathematics and System Engineering.
Funding Statement
This work is part of the multidisciplinary ecosystem to study lifecourse determinants and prevention of early-onset burdensome multimorbidity (MELD-B) project which is supported by the National Institute for Health Research (NIHR203988). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for this work has been obtained from the University of Southampton Faculty of Medicine Ethics committee (ERGO II Reference 66810).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The manuscript has undergone changes to elements of the analysis and reporting.
Data Availability
The BCS70 datasets generated and analysed in the current study are available from the UK Data Archive repository (available here: http://www.cls.ioe.ac.uk/page.aspx?&sitesectionid=795).
